Live Quote · NASDAQPBLSHealthcare· Biotechnology

Parabilis Medicines, Inc.

$30.57 0.69%(+$0.21)
TickerSpark Score

Limited financial coverage for PBLS.

Not enough data to compute a meaningful composite — typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available stats still render below.

80
Momentum
52-Week Range61% of range
Low
$24.51
Current
$30.57
High
$34.47
Company Overviewwww.parabilismed.com

About the company

Fog Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them.

CEO
Mathai Mammen
IPO
2026
Employees
145
HQ
Cambridge, MA, US

Price Chart

+52.85% · this period
$31.60$25.80$20.00Jun 08Jun 24Jul 10
Performance & Tape
52W High
$34.47
52W Low
$24.51
50D MA
$28.35
200D MA
$28.35
Beta
0.00
Avg Volume
1.11M
AI Analysis · PBLS

AI snapshot

Six angles, distilled from the data.

Technical Setup

PBLS is in a constructive post-IPO trend, holding above its 200-day moving average and trading in the upper half of its 52-week range. The setup favors a stock still working through price discovery, with the recent base built well above the yearly low and below the high.

Analyst Consensus

Street coverage is newly positive, with Leerink, Guggenheim, and Evercore all starting the name at Outperform or Buy. The target cluster is tightly grouped at $40, above the current share price, which points to upside bias rather than a split view.

Earnings Watch

No earnings beat/miss history is available yet, and next-year EPS is still expected to be negative at -1.9 versus -1.77 TTM. Shareholders should watch for clinical progress, cash burn, and whether management can narrow losses as the pipeline advances.

Insider Pulse

No notable insider buying or selling in recent quarters. With no reported transactions, the tape does not currently signal a meaningful discretionary insider view.

Financial Health

Profitability remains deeply negative, with EPS at -1.77 TTM and no reported margin profile yet. Cash burn is the key watchpoint: operating cash flow was -$123.7 million in 2025, while cash and equivalents stood at $27.7 million.

Peer Snapshot

As a clinical-stage biotech, PBLS is valued on pipeline execution rather than current earnings power. The stock trades at a negative P/E and sits below the $40 analyst target cluster, leaving valuation tied to trial and platform milestones.

Coverage · PBLS

Our PBLS coverage

Recent articles, reports, and earnings notes.

View all →
For Active Investors

Want a deeper read on PBLS?

Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.

Generate PBLS report →

AI analysis · Last refreshed July 12, 2026 · Live quote · Not investment advice